The numbers tell a jarring story. Rocket Lab’s stock closed at €56.40 on Friday, shedding 8.29% in a single session and pushing the monthly decline to nearly 25%. From the 52-week high of €133.80 reached on May 27, the shares have cratered almost 58%. Yet the company just landed a $266 million fixed-price contract with the U.S. Space Force for suborbital launches — covering twelve rockets plus six optional missions — alongside a slot in the third phase of the National Security Space Launch program. The disconnect between operational momentum and market sentiment has rarely been starker.
A Sector-Wide Rotation, Not a Company-Specific Crisis
The selloff looks less like a verdict on Rocket Lab’s execution and more like a broader reassessment of speculative space stocks. Piper Sandler analyst Alexander Potter initiated coverage of both Rocket Lab and rival AST SpaceMobile this week, handing Rocket Lab a “Neutral” rating while signaling a preference for the competitor. Both stocks tumbled on Thursday. Peer companies across the space sector have suffered similar drawdowns, suggesting capital is rotating out of high-beta names toward newer, shinier alternatives — a dynamic that hurts all players regardless of individual fundamentals.
The technical damage is undeniable. The stock now trades below all major moving averages, including the 200-day line at €67.36 — a textbook bearish configuration. The 50-day average sits at €89.05, a full 37% above the current price. A gap that wide typically signals either a broken trend or a stock that has been sold far more aggressively than the underlying business has changed. The 14-day RSI of 30.8 confirms oversold conditions, while annualized 30-day volatility of roughly 88% underscores that raw emotion, not orderly profit-taking, is driving the action.
Neutron: The Risk That Won’t Go Away
The bear case hinges on one variable: Neutron, the medium-lift rocket that represents Rocket Lab’s path beyond the small-satellite niche. The timeline has slipped before, with the first flight now targeted for the fourth quarter of 2026. Hardware setbacks during the year included the loss of components intended for flight use. CEO Peter Beck has pointed investors toward the test stands as the key indicator — a tacit acknowledgment that the market is watching Neutron’s schedule as the single most important sentiment driver.
Five commercial missions are already booked before the first flight, and the order book is filling fast. But a rocket program under this level of scrutiny is precisely the kind of execution risk that punishes premium valuations disproportionately once sentiment sours — and it has soured. The difference between a delay funded from a strong balance sheet and one that forces dilution is critical, and Rocket Lab has the former: a $2.2 billion backlog and more than $2 billion in available liquidity as of the first-quarter report. That financial cushion buys time for additional qualification work, but it doesn’t buy investor patience.
Should investors sell immediately? Or is it worth buying Rocket Lab?
The Forgotten Context
Lost in the panic over the monthly decline is a simple fact: the stock is still up 37.56% over twelve months. That is not a broken growth story unwinding from a bubble peak. It is a highly volatile stock giving back part of an extraordinary rally that followed euphoric buying around sector-wide catalysts, including investor attention on SpaceX’s IPO. Once that rotation effect fades, Rocket Lab’s own contract wins and growing backlog should reassert themselves as the primary drivers of the share price.
The consensus analyst price target stands at €100.53 — representing roughly 78% upside from current levels. A second source puts the 17-analyst consensus at €114.33, implying similar potential. Either way, the spread is so wide that either the analysts are dramatically wrong or the market has overshot to the downside. Given the steady stream of defense and commercial contracts arriving even amid the selloff, the latter explanation carries more weight.
Overbought in Fear, Not in Value
Oversold conditions alone don’t guarantee a bounce. At nearly 90% annualized volatility, sharp reversals in either direction are the norm, not the exception. Historically, such readings can trigger powerful relief rallies — but they can also persist for weeks without a confirmed short-term catalyst to shift sentiment. The stock is trading 16% below its 200-day moving average while its order book and government contract pipeline continue to expand. That looks more like a sentiment-driven overreaction than a fundamental break.
For investors with tolerance for turbulence, the current setup argues for riding out the storm rather than capitulating into it. The real risks remain: Neutron’s first flight has already been delayed once, SpaceX competition is relentless, and at this volatility level, violent swings in both directions are guaranteed. But a stock that has shed 58% from its high while its business wins record contracts and builds a $2.2 billion backlog is not a company in crisis. It is a company whose stock is being punished for factors largely outside its control — and that gap between price and value is exactly what patient capital is designed to exploit.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from July 25 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 25.
Rocket Lab: Buy or sell? Read more here...
